Multiple Sclerosis: Patient-reported outcomes
Patient-reported outcomes after stem cell therapy for Multiple Sclerosis, based on 27 patients in our follow-up registry.
Updated ·
Overall patient-reported outcomes
Physical condition
reported physical improvement
56%
N = 27
Quality of life
reported quality-of-life improvement
50%
N = 26
Treatment satisfaction
satisfied with the treatment outcome
56%
N = 25
Reported change vs. before treatment
Worse No change Small Moderate Significant
| Symptom | Reported change vs. before treatment | Reported improvement |
|---|---|---|
| Movement in general | | 83% |
| Limb muscle strength | | 83% |
| Hand control | | 67% |
| Overall strength | | 67% |
| Swallowing | | 60% |
| Speaking | | 55% |
| Urinary incontinence | | 47% |
| Loss of sensitivity | | 46% |
| Cognitive impairment | | 44% |
| Numbness | | 43% |
| Muscle weakness | | 41% |
| Muscle spasms | | 40% |
| Bowel control | | 40% |
| Body pain | | 39% |
| Coordination | | 37% |
| Balance | | 35% |
| Low mood or anxiety | | 32% |
| Fatigue | | 32% |
About this data
Patients self-assess each symptom on a 5-point scale (Worse / No improvement / Small / Moderate / Significant) at follow-up checkpoints after treatment, comparing to their pre-treatment baseline. "Reported improvement" combines the small, moderate and significant buckets. Data is updated daily from our internal patient registry. As with any medical treatment, past results do not guarantee future outcomes — improvements vary from patient to patient.
